MoonLake Immunotherapeutics. (MLTX) NASDAQ

$40.69 (0.08) (-0.20%)

Market Cap: $2.56B

As of 05/15/24 04:00 PM EDT. Market closed.

(MLTX)

MoonLake Immunotherapeutics. (MLTX)
NASDAQ

$40.69
(0.08) (-0.20%)

Market Cap: $2.56B

As of 05/15/24 04:00 PM EDT. Market closed.

Add to Portfolio

moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint ... read more

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
14
URL
Address
.
PRICE CHART FOR MOONLAKE IMMUNOTHERAPEUTICS
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$40.77
Days Range
$40.64 - $42
52 week range
$24.31 - $64.98
Volume
12
Avg. Volume (30 days)
297,264
Market Cap
$2.56B
Dividend Yield
-
P/E
-
Shares Outstanding
62,874,637
Open
-
Previous Close
$40.77
Days Range
$40.64 - $42
52 week range
$24.31 - $64.98
Volume
12
Avg. Volume (30 days)
297,264
Market Cap
$2.56B
Dividend Yield
-
P/E
-
Shares Outstanding
62,874,637
FINANCIAL STATEMENTS FOR MOONLAKE IMMUNOTHERAPEUTICS
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR MOONLAKE IMMUNOTHERAPEUTICS
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Santos da Silva JorgeChief Executive OfficerFeb 29, 2024 Sale$55.894,740264,9192,982,814Feb 29, 2024, 07:56 PM
Santos da Silva JorgeChief Executive OfficerFeb 28, 2024 Sale$55.0056,0653,083,5752,987,554Feb 29, 2024, 07:56 PM
Santos da Silva JorgeChief Executive OfficerFeb 27, 2024 Sale$55.0062,8103,454,5503,043,619Feb 29, 2024, 07:56 PM
Reich KristianChief Scientific OfficerFeb 27, 2024 Sale$55.0029,4311,618,70570,071Feb 29, 2024, 07:53 PM
Reich KristianChief Scientific OfficerFeb 27, 2024 Sale$55.0029,4911,622,0052,957,483Feb 29, 2024, 07:53 PM
Reich KristianChief Scientific OfficerFeb 28, 2024 Sale$55.0028,0901,544,95041,981Feb 29, 2024, 07:53 PM
Reich KristianChief Scientific OfficerFeb 28, 2024 Sale$55.0031,9101,755,0502,925,573Feb 29, 2024, 07:53 PM
Santos da Silva JorgeChief Executive OfficerFeb 21, 2024 Sale$55.271,12562,1793,106,429Feb 23, 2024, 04:48 PM
Reich KristianChief Scientific OfficerFeb 20, 2024 Sale$57.4510,000574,5002,987,483Feb 22, 2024, 06:32 PM
Reich KristianChief Scientific OfficerFeb 21, 2024 Sale$55.3056931,46699,502Feb 22, 2024, 06:32 PM
Reich KristianChief Scientific OfficerFeb 21, 2024 Sale$55.3150928,1532,986,974Feb 22, 2024, 06:32 PM
Reich KristianChief Scientific OfficerFeb 20, 2024 Sale$57.4310,000574,300100,071Feb 22, 2024, 06:32 PM
Santos da Silva JorgeChief Executive OfficerFeb 20, 2024 Sale$57.4420,0001,148,8003,107,554Feb 20, 2024, 06:36 PM
Santos da Silva JorgeChief Executive OfficerFeb 16, 2024 Sale$60.1520,0001,203,0003,127,554Feb 20, 2024, 06:36 PM
Santos da Silva JorgeChief Executive OfficerFeb 15, 2024 Sale$60.1820,0001,203,6003,147,554Feb 20, 2024, 06:36 PM
Reich KristianChief Scientific OfficerFeb 15, 2024 Sale$60.1710,000601,7003,007,483Feb 16, 2024, 06:02 PM
Reich KristianChief Scientific OfficerFeb 14, 2024 Sale$62.4310,000624,300130,071Feb 16, 2024, 06:02 PM
Reich KristianChief Scientific OfficerFeb 14, 2024 Sale$62.4210,000624,2003,017,483Feb 16, 2024, 06:02 PM
Reich KristianChief Scientific OfficerFeb 16, 2024 Sale$60.1510,000601,500110,071Feb 16, 2024, 06:02 PM
Reich KristianChief Scientific OfficerFeb 16, 2024 Sale$60.1510,000601,5002,997,483Feb 16, 2024, 06:02 PM
Reich KristianChief Scientific OfficerFeb 15, 2024 Sale$60.1610,000601,600120,071Feb 16, 2024, 06:02 PM
Bodenstedt MatthiasChief Financial OfficerDec 20, 2023 Sale$58.345,264307,102520,903Dec 21, 2023, 04:01 PM
Bodenstedt MatthiasChief Financial OfficerDec 19, 2023 Sale$59.2294,7365,610,266526,167Dec 21, 2023, 04:01 PM
Chen Bihua10% OwnerOct 05, 2023 Buy$59.9058,8393,524,2978,494,151Oct 10, 2023, 04:00 PM
Chen Bihua10% OwnerOct 04, 2023 Buy$57.3267,8143,887,0178,435,312Oct 04, 2023, 05:52 PM
Chen Bihua10% OwnerOct 03, 2023 Buy$57.25150,4878,615,6828,367,498Oct 04, 2023, 05:52 PM
Chen Bihua10% OwnerOct 02, 2023 Buy$57.3774,9114,297,6448,217,011Oct 04, 2023, 05:52 PM
Chen Bihua10% OwnerJun 26, 2023 Buy$45.63450,00020,535,0114,127,100Jun 28, 2023, 06:28 PM
Chen Bihua10% OwnerMar 21, 2023 Buy$21.70238,5115,175,9993,677,100Mar 22, 2023, 05:07 PM
Chen Bihua10% OwnerMar 20, 2023 Buy$19.71588,58911,598,8473,438,589Mar 22, 2023, 05:07 PM
Chen Bihua10% OwnerApr 05, 2022 Buy$10.002,850,00028,500,0002,850,000Apr 07, 2022, 06:26 PM
Chen BihuaCEO and ChairmanOct 22, 2020 Buy$10.00430,0004,300,000430,000Oct 22, 2020, 05:10 PM
Helix Holdings LLCDirectorOct 22, 2020 Buy$10.00430,0004,300,000430,000Oct 22, 2020, 05:08 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Santos da Silva JorgeChief Executive Officer02/29/2024264,919
Santos da Silva JorgeChief Executive Officer02/28/20243,083,575
Santos da Silva JorgeChief Executive Officer02/27/20243,454,550
Reich KristianChief Scientific Officer02/27/20241,618,705
Reich KristianChief Scientific Officer02/27/20241,622,005
Reich KristianChief Scientific Officer02/28/20241,544,950
Reich KristianChief Scientific Officer02/28/20241,755,050
Santos da Silva JorgeChief Executive Officer02/21/202462,179
Reich KristianChief Scientific Officer02/20/2024574,500
Reich KristianChief Scientific Officer02/21/202431,466
Reich KristianChief Scientific Officer02/21/202428,153
Reich KristianChief Scientific Officer02/20/2024574,300
Santos da Silva JorgeChief Executive Officer02/20/20241,148,800
Santos da Silva JorgeChief Executive Officer02/16/20241,203,000
Santos da Silva JorgeChief Executive Officer02/15/20241,203,600
Reich KristianChief Scientific Officer02/15/2024601,700
Reich KristianChief Scientific Officer02/14/2024624,300
Reich KristianChief Scientific Officer02/14/2024624,200
Reich KristianChief Scientific Officer02/16/2024601,500
Reich KristianChief Scientific Officer02/16/2024601,500
Reich KristianChief Scientific Officer02/15/2024601,600
Bodenstedt MatthiasChief Financial Officer12/20/2023307,102
Bodenstedt MatthiasChief Financial Officer12/19/20235,610,266
Chen Bihua10% Owner10/05/20233,524,297
Chen Bihua10% Owner10/04/20233,887,017
Chen Bihua10% Owner10/03/20238,615,682
Chen Bihua10% Owner10/02/20234,297,644
Chen Bihua10% Owner06/26/202320,535,011
Chen Bihua10% Owner03/21/20235,175,999
Chen Bihua10% Owner03/20/202311,598,847
Chen Bihua10% Owner04/05/202228,500,000
Chen BihuaCEO and Chairman10/22/20204,300,000
Helix Holdings LLCDirector10/22/20204,300,000
Load More Insider Transactions
FUNDS WITH A POSITION IN MOONLAKE IMMUNOTHERAPEUTICS
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
ADAGE CAPITAL PARTNERS GP, L.L.C.2,284,9130.22%49.76%Other
HOLOCENE ADVISORS, LP1,454,8690.27%51.34%Growth At A Reasonable Price
BALYASNY ASSET MANAGEMENT L.P.424,6950.04%-29.04%Event Driven
BLACKROCK INC.408,2800.00048%6.96%Other
CANDRIAM S.C.A.239,0000.08%29.19%Other
SENATOR INVESTMENT GROUP LP155,0000.4%ExitedEvent Driven, Value
D. E. SHAW & CO., INC.128,7000.00679%ExitedOther
TIG ADVISORS, LLC5,100 (Call)0.02%-95.18%Event Driven
SOROS FUND MANAGEMENT LLC100,0000.08%ExitedOther
DUQUESNE FAMILY OFFICE LLC87,5000.1%NewOther
GEODE CAPITAL MANAGEMENT, LLC54,0260.00025%10.77%Other
ALPS ADVISORS INC42,2730.02%8.68%Other
TUDOR INVESTMENT CORP ET AL31,4110.01%4.17%Event Driven, Other
SAND GROVE CAPITAL MANAGEMENT LLP20,0000.32%ExitedValue
AQR CAPITAL MANAGEMENT LLC5,8580.0005%-9.71%Other
FARALLON CAPITAL MANAGEMENT LLC3,4000.00097%ExitedEvent Driven, Value
CHANGE IN SHARES OUTSTANDING FOR MOONLAKE IMMUNOTHERAPEUTICS
STOCK BUYBACKS FOR MOONLAKE IMMUNOTHERAPEUTICS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
-8.21%
1Q
12/31/2023
06/30/2023
12.36%
2Q
12/31/2023
03/31/2023
25.76%
3Q
12/31/2023
09/30/2022
33.03%
5Q
12/31/2023
06/30/2022
39.55%
6Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
-8.21%
1Q
06/30/2023
12.36%
2Q
03/31/2023
25.76%
3Q
09/30/2022
33.03%
5Q
06/30/2022
39.55%
6Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR MOONLAKE IMMUNOTHERAPEUTICS
LOADING...